EuroFlow

EuroFlow consortium was founded in 2005 as 2U-FP6 funded project and launched in spring 2006. At first, EuroFlow was composed of 18 diagnostic research groups

EuroFlow consortium was founded in 2005 as 2U-FP6 funded project and launched in spring 2006. At first, EuroFlow was composed of 18 diagnostic research groups and two SMEs (small/medium enterprises) from eight different European countries with complementary knowledge and skills in the field of flow cytometry and immunophenotyping. During 2012 both SMEs left the project so it obtained full scientific independence. The goal of EuroFlow consortium is to innovate and standardize flow cytometry leading to global improvement and progress in diagnostics of haematological malignancies and individualisation of treatment.

Background

Since the '90s immunophenotyping (staining cells with antibodies conjugated with fluorochromes and detection with flow cytometer) became the preferred method in diagnostics of haematological malignancies. The advantages of this method are speed and simplicity, possibility to measure more than 6 parameters at a time, precise focusing on malignant population and also broad applicability in diagnostics. Because there is a great progress in development of antibodies, fluorochromes and multicolor digital flow cytometers, it became a question of how to interpret cytometric data and how to achieve comparable results between facilities. Even though a consensus of recommendations and guidelines was established, standardization was only partial because there was no regard of different antibody clones, fluorochromes and their optimal combinations or of sample preparation. On that account cytometry is perceived as method highly dependent on level of expertise and with limited reproducibility in multicentric studies.

Goals of Euroflow

These goals were set out in the journal Leukemia in 2012.[1]

  • Development and evaluation of new antibodies
  • Establishment of new immunobead assay technology
  • Development of new software tools followed by new analysing approaches for recognition of complex immunophenotype patterns.
  • Design of new multicolor protocols and standard operating procedures (SOPs)
  • Development and standardization of fast, accurate and highly sensitive flow cytometry

Achievements

During passed few years EuroFlow achieved most of its goals. Eight-color panels for diagnoses, and classification and follow-up of haematological malignancies were established.[2] Panels, consisting of screening tube and supplementary characterisation tubes, are based on experiences and knowledge from literature but further optimised and tested in multiple research centers on large collection of samples impeaching on selection of fluorochromes and standardization of instrument settings and SOPs.[3] Antibody clones, fluorochromes and other reagencies from different companies underwent detailed testing and comparison. Simultaneously a new software for analysing of more complex and extensive data files was developed, capable of multidimensional statistical comparison of normal data samples and patient samples.[4][5] Also new antibody clones against rigorously selected epitopes of proteins involved in chromosomal translocations were developed for detection of most frequent fusion proteins in acute leukemia and chronic myeloid leukemia. Also detection of fusion proteins using immunobead assays was introduced.[6][7][8]

References

  1. ^ Van Dongen, J J M; Orfao, A; Euroflow, Consortium (2012). "EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine". Leukemia. 26 (9): 1899–907. doi:10.1038/leu.2012.121. PMC 3437406. PMID 22948488.
  2. ^ Van Dongen, J J M; Lhermitte, L; Böttcher, S; Almeida, J; Van Der Velden, V H J; Flores-Montero, J; Rawstron, A; Asnafi, V; Lécrevisse, Q; Lucio, P; Mejstrikova, E; Szczepański, T; Kalina, T; De Tute, R; Brüggemann, M; Sedek, L; Cullen, M; Langerak, A W; Mendonça, A; MacIntyre, E; Martin-Ayuso, M; Hrusak, O; Vidriales, M B; Orfao, A (2012). "EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes". Leukemia. 26 (9): 1908–75. doi:10.1038/leu.2012.120. PMC 3437410. PMID 22552007.
  3. ^ Kalina, T; Flores-Montero, J; Van Der Velden, V H J; Martin-Ayuso, M; Böttcher, S; Ritgen, M; Almeida, J; Lhermitte, L; Asnafi, V; Mendonça, A; De Tute, R; Cullen, M; Sedek, L; Vidriales, M B; Pérez, J J; Te Marvelde, J G; Mejstrikova, E; Hrusak, O; Szczepański, T; Van Dongen, J J M; Orfao, A (2012). "EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols". Leukemia. 26 (9): 1986–2010. doi:10.1038/leu.2012.122. PMC 3437409. PMID 22948490.
  4. ^ Pedreira, Carlos E.; Costa, Elaine S.; Barrena, Susana; Lecrevisse, Quentin; Almeida, Julia; Van Dongen, Jacques J. M.; Orfao, Alberto; Euroflow, Consortium (2008). "Generation of flow cytometry data files with a potentially infinite number of dimensions". Cytometry Part A. 73A (9): 834–46. doi:10.1002/cyto.a.20608. PMID 18629843. S2CID 12560225.
  5. ^ Costa, E S; Pedreira, C E; Barrena, S; Lecrevisse, Q; Flores, J; Quijano, S; Almeida, J; Del Carmen García-Macias, M; Bottcher, S; Van Dongen, J J M; Orfao, A (2010). "Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: A step forward in the standardization of clinical immunophenotyping". Leukemia. 24 (11): 1927–33. doi:10.1038/leu.2010.160. PMC 3035971. PMID 20844562.
  6. ^ Dekking, E.; Van Der Velden, V.H.J.; Böttcher, S.; Brüggemann, M.; Sonneveld, E.; Koning-Goedheer, A.; Boeckx, N.; Lucio, P.; Sedek, L.; Szczepański, T.; Kalina, T.; Kovac, M.; Evans, P.; Hoogeveen, P.G.; Flores-Montero, J.; Orfao, A.; Comans-Bitter, W.M.; Staal, F.J.T.; Van Dongen, J.J.M. (2010). "Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay". Best Practice & Research Clinical Haematology. 23 (3): 333–45. doi:10.1016/j.beha.2010.09.010. PMID 21123134.
  7. ^ Dekking, E H A; Van Der Velden, V H J; Varro, R; Wai, H; Böttcher, S; Kneba, M; Sonneveld, E; Koning, A; Boeckx, N; Van Poecke, N; Lucio, P; Mendonça, A; Sedek, L; Szczepański, T; Kalina, T; Kanderová, V; Hoogeveen, P; Flores-Montero, J; Chillón, M C; Orfao, A; Almeida, J; Evans, P; Cullen, M; Noordijk, A L; Vermeulen, P M; De Man, M T; Dixon, E P; Comans-Bitter, W M; Van Dongen, J J M (2012). "Flow cytometric immunobead assay for fast and easy detection of PML–RARA fusion proteins for the diagnosis of acute promyelocytic leukemia". Leukemia. 26 (9): 1976–85. doi:10.1038/leu.2012.125. PMC 3437408. PMID 22948489.
  8. ^ Weerkamp, F; Dekking, E; Ng, Y Y; Van Der Velden, V H J; Wai, H; Böttcher, S; Brüggemann, M; Van Der Sluijs, A J; Koning, A; Boeckx, N; Van Poecke, N; Lucio, P; Mendonça, A; Sedek, L; Szczepański, T; Kalina, T; Kovac, M; Hoogeveen, P G; Flores-Montero, J; Orfao, A; MacIntyre, E; Lhermitte, L; Chen, R; Brouwer-De Cock, K A J; Van Der Linden, A; Noordijk, A L; Comans-Bitter, W M; Staal, F J T; Van Dongen, J J M; Euroflow, Consortium (2009). "Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients". Leukemia. 23 (6): 1106–17. doi:10.1038/leu.2009.93. PMID 19387467.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.